Advertisement

Response to Letter to Editor re: “Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms”

Published:February 26, 2022DOI:https://doi.org/10.1016/j.acra.2022.02.001
      Dear Dr. Dunnick, We appreciate the thoughtful comments by Chan and colleagues regarding the methodology of our recently published paper on the combined use of 18F-FDG and 68Ga-DOTATATE PET/CT for prognostication in G3 GEP-NENs (
      • Lee H
      • Nakamoto R
      • Moore SE
      • et al.
      Combined Quantification of (18)F-FDG and (68)Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms.
      ). We believe that clarification of the methodological issues raised will facilitate adoption of the FDZ score into the clinical setting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lee H
        • Nakamoto R
        • Moore SE
        • et al.
        Combined Quantification of (18)F-FDG and (68)Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms.
        Acad Radiol. 2021;
        • Menda Y
        • Ponto LL
        • Schultz MK
        • et al.
        Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.
        Pancreas. 2013; 42: 937-943
        • Haug AR
        • Rominger A
        • Mustafa M
        • et al.
        Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.
        J Nucl Med. 2011; 52: 1679-1683
        • Singh S
        • Hallet J
        • Rowsell C
        • et al.
        Variability of Ki67 labeling index in multiple neuroendocrine tumors specimens over the course of the disease.
        Eur J Surg Oncol. 2014; 40: 1517-1522
        • Chan DL
        • Pavlakis N
        • Schembri GP
        • et al.
        Dual somatostatin receptor/FDG PET/ct imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.
        Theranostics. 2017; 7: 1149-1158
        • Carlsen EA
        • Johnbeck CB
        • Loft M
        • et al.
        Semiautomatic tumor delineation for evaluation of (64)Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume.
        J Nucl Med. 2021; 62: 1564-1570
        • Lee H
        • JR Eads
        • Pryma DA.
        (68) Ga-dotatate positron emission tomography-computed tomography quantification predicts response to somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors.
        Oncologist. 2021; 26: 21-29
        • Doot RK
        • Scheuermann JS
        • Christian PE
        • et al.
        Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT.
        Med Phys. 2010; 37: 6035-6046